What is Avemar Pulvis?
Avemar pulvis is a fermented wheat germ extract (FWGE) that is NOT recommended as a standard cancer treatment supplement based on major oncology guidelines, which advise against routine dietary supplements during cancer treatment due to lack of evidence for reducing recurrence and potential interference with chemotherapy. 1, 2
Product Description
Avemar pulvis is a powder consisting of an aqueous extract of fermented wheat germ, standardized to contain approximately 200 micrograms per gram of 2,6-dimethoxy-p-benzoquinone (a benzoquinone derivative). The product includes drying aids maltodextrin and silicon dioxide. 3
- Regulatory Status: Approved in Hungary, Czech Republic, Bulgaria, and Romania as a "medical nutriment for cancer patients" since 1998
- U.S. Status: Has "Generally Recognized as Safe" (GRAS) status as a dietary supplement ingredient 3
- European Status: Listed in EFSA novel food Catalogue 4
Guideline Position on Cancer Supplements
Major cancer organizations explicitly advise AGAINST routine supplement use during cancer treatment:
American Cancer Society Position 1
- Many cancer experts advise patients NOT to take supplements during treatment
- No evidence supports taking supplements after cancer diagnosis to reduce recurrence risk
- Supplements may contain substances that affect chemotherapy drugs
- Most studies show risks of high-dose supplements outweigh benefits
- If supplements are used, should not exceed 100% of daily value
ESPEN Guidelines Position 2
- Unconditional artificial nutrition/supplementation in all patients undergoing anticancer therapy is associated with more harm than benefit and should be avoided
- Nutritional support should focus on adequate energy and protein intake through food, oral nutritional supplements, or medical nutrition when indicated
- No specific recommendation for fermented wheat germ extract or similar products
Research Evidence (Limited and Inconsistent)
While some small studies suggest potential benefits, the evidence is insufficient to recommend Avemar:
Reported Dosing in Studies
- Standard dose: 8.5 grams per day (approximately 121 mg/kg body weight for a 70 kg individual) 3
- Duration: Typically 9-12 months in clinical trials 5, 6
Small Clinical Studies
- Colorectal cancer: One small study (66 patients) showed reduced recurrence and metastases 5
- Melanoma: Pilot study (phase II) showed improved progression-free survival when added to chemotherapy 6
- Prostate cancer: Pilot study in 36 CRPC patients showed possible PSADT extension in 65% 7
- Critical limitation: All studies were small, pilot-phase, and lack the rigor of large randomized controlled trials
Safety Profile
Toxicology studies showed no adverse effects at doses up to 25-fold higher than recommended human dose in rodents. 3 Clinical studies reported only mild gastrointestinal side effects in some patients. 5 However, high concentrations may have prooxidant effects. 8
Clinical Caveats and Pitfalls
Key concerns that align with guideline recommendations:
Drug Interactions: Up to 68% of physicians are unaware of supplement use among cancer patients 9, creating risk for undisclosed interactions with chemotherapy
Lack of Documentation: Supplements are infrequently documented in medical records 10, compromising medication reconciliation and patient safety
Insufficient Evidence: The systematic review concluded that while FWGE may possess therapeutic potential, the strength of evidence remains limited - only 2 of 6 human studies demonstrated high methodological quality 4
Mechanism Concerns: While proposed to disrupt glucose metabolism in cancer cells, the same mechanisms could theoretically affect normal cells or interfere with treatment efficacy
Practical Recommendation
If a cancer patient is considering or using Avemar pulvis:
- Mandatory disclosure to the oncology team before starting
- Document in medical record as part of medication reconciliation 10
- Prioritize evidence-based nutritional support (adequate calories, protein) through food first 1, 2
- Consider registered dietitian consultation for individualized nutritional assessment 1
- Recognize this is NOT a substitute for standard cancer treatment
- Monitor for any gastrointestinal side effects
- Discontinue if any concerning interactions or adverse effects occur
The evidence does not support routine recommendation of Avemar pulvis as part of standard cancer care, consistent with major oncology guideline positions on dietary supplements during cancer treatment.